Reductions in migraine and headache days in chronic migraine patients with and without prior migraine preventive treatment use: Subgroup analysis of the HALO CM study

被引：0
|
作者：
Jenkins, B. [1 ]
Cohen, J. M. [2 ]
Yang, R. [3 ]
Ramirez-Campos, V. [3 ]
机构：
[1] North Shore Vertigo & Neurol Clin, Neurol, St Leonards, NSW, Australia
[2] Teva Pharmaceut Ind, Global Med Affairs, Frazer, PA USA
[3] Teva Pharmaceut Ind, Global Clin Dev, Frazer, PA USA
来源：
JOURNAL OF THE NEUROLOGICAL SCIENCES | 2019年 / 405卷
关键词：
D O I：
10.1016/j.jns.2019.10.1669
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
WCN19-1590
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Reduction in acute headache medication use with fremanezumab in chronic migraine patients by prior migraine preventive treatment use: Subgroup analysis of the HALO CM study
    Stark, R.
    Cohen, J. M.
    Yang, R.
    Ramirez-Campos, V.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [2] Onabotulinumtoxin a for treatment of chronic migraine (cm): analysis of the preempt chronic migraine subgroup with and without prior migraine prophylactic treatment
    Aurora, S. K.
    Silberstein, S. D.
    DeGryse, R. E.
    Turkel, C. C.
    [J]. CEPHALALGIA, 2011, 31 (01) : 18 - 19
  • [3] The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study
    Stephen D. Silberstein
    Joshua M. Cohen
    Michael J. Seminerio
    Ronghua Yang
    Sait Ashina
    Zaza Katsarava
    [J]. The Journal of Headache and Pain, 2020, 21
  • [4] The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study
    Silberstein, Stephen D.
    Cohen, Joshua M.
    Seminerio, Michael J.
    Yang, Ronghua
    Ashina, Sait
    Katsarava, Zaza
    [J]. JOURNAL OF HEADACHE AND PAIN, 2020, 21 (01):
  • [5] Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study
    Lipton, Richard B.
    Cohen, Joshua M.
    Galic, Maja
    Seminerio, Michael J.
    Yeung, Paul P.
    Aycardi, Ernesto
    Bigal, Marcelo E.
    Bibeau, Kristen
    Buse, Dawn C.
    [J]. HEADACHE, 2021, 61 (04): : 662 - 672
  • [6] Real-world Reductions in Migraine and Headache Days for Patients With Chronic and Episodic Migraine Initiating Fremanezumab in the US
    Cohen, Joshua M.
    Thompson, Stephen
    Patterson-Lomba, Oscar
    Driessen, Maurice
    Seminerio, Michael
    Carr, Karen
    Mu, Fan
    [J]. NEUROLOGY, 2021, 96 (15)
  • [7] Patients with Chronic Migraine Improving to 4 Monthly Headache Days is an Effective Treatment Goal for Chronic Migraine
    Seng, Elizabeth
    Singer, Alexandra B.
    Grinberg, Amy S.
    Buse, Dawn C.
    Marzouk, Maya
    Wells, Rebecca E.
    Lipton, Richard B.
    [J]. ANNALS OF NEUROLOGY, 2022, 92 : S41 - S42
  • [8] Real-world Reductions in Migraine and Headache Days for Patients With Migraine Initiating Fremanezumab in Germany
    Heinze, A.
    Totev, T.
    Krasenbaum, L.
    Terasawa, E.
    Akcicek, H.
    Hipp, J.
    Sun, R.
    Yim, E.
    Driessen, M.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 419 - 419
  • [9] Eptinezumab Reduced the Frequency of Migraine Days in Patients With Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
    Diener, H.
    Marmura, M.
    Hirman, J.
    Mehta, L.
    Brevig, T.
    Brunner, E.
    Cady, R.
    [J]. HEADACHE, 2020, 60 : 107 - 107
  • [10] Eptinezumab Reduced the Frequency of Migraine Days in Patients with Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
    Diener, H. -C.
    Marmura, M.
    Hirman, J.
    Mehta, L.
    Brevig, T.
    Brunner, E.
    Cady, R.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 155 - 155
12345